Could less chemo be better? new trial aims to reduce treatment burden for brain lymphoma
NCT ID NCT04931368
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase III trial tests whether a de-escalated (less intense) version of the standard MATRix chemotherapy regimen works as well for newly diagnosed primary CNS lymphoma. About 331 patients will receive either the standard four courses of MATRix or a reduced schedule with one course of rituximab/high-dose methotrexate followed by two courses of MATRix. The goal is to see if the gentler approach improves event-free survival while reducing side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Rituximab and high-dose methotrexate (MATRix regimen)
What this could lead to
If successful, this could show that a less intense chemotherapy regimen works as well as the standard, reducing side effects for patients with primary CNS lymphoma.
What could go wrong
This is an early-stage Phase III trial with 331 participants. The de-escalated approach may prove less effective, and results may not apply to all patients. Chemotherapy still carries significant risks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Klinikum Stuttgart
Stuttgart, Baden-Wurttemberg, 70174, Germany